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Cancer associated fibroblasts (CAFs) are the main stromal cell type of solid tumour microenvironment and undergo an activation
process associated with secretion of growth factors, cytokines, and paracrine interactions. One of the important features of solid
tumours is the metabolic reprogramming that leads to changes of bioenergetics and biosynthesis in both tumour cells and CAFs.
In particular, CAFs follow the evolution of tumour disease and acquire a catabolic phenotype: in tumour tissues, cancer cells and
tumour microenvironment form a network where the crosstalk between cancer cells and CAFs is associated with cell metabolic
reprogramming that contributes to CAFs activation, cancer growth, and progression and evasion from cancer therapies. In this
regard, the study of CAFs metabolic reprogramming could contribute to better understand their activation process, the interaction
between stroma, and cancer cells and could offer innovative tools for the development of new therapeutic strategies able to eradicate
the protumorigenic activity of CAFs. Therefore, this review focuses on CAFs metabolic reprogramming associated with both
differentiation process and cancer and stromal cells crosstalk. Finally, therapeutic responses and potential anticancer strategies
targeting CAFs metabolic reprogramming are reviewed.
1. Introduction
In 1927, Warburg et al. reported that glucose metabolism
was significantly enhanced in tumour cells compared with
normal tissue, even in the presence of sufficient oxygen [1,
2]. This process known as “Warburg effect” is the principal
and metabolic characteristic of cancer and is associated
with metabolic reprogramming of cancer cells [3]. Moreover,
other metabolic adaptations have been described in tumour
tissues, such as the use of alternative carbon sources and
the establishment of metabolic interactions between tumour
and stromal cells represented by the “reverse Warburg
effect” [3, 4]. Therefore, solid tumours can be described
as metabolically heterogeneous diseases, in which several
energetic pathways of tumour microenvironment collaborate
[5, 6].
Furthermore, tumour microenvironment, including
blood and lymphatic tumour vessels, extracellular matrix
(ECM), and noncancer stromal cells such as cancer associated
fibroblasts (CAFs), modulates cancer growth, progression,
and evasion from cancer therapies [7]. In particular, CAFs
are the major tumour stromal cells and are also prone, such
as the cancer cells, to metabolic reprogramming leading to
glycolysis switch [8]. Moreover, recent studies have showed
the important role of CAFs in tumour initiation, progression,
and metastasis [7, 9, 10].
From this point of view, the study of metabolic repro-
gramming that regulates CAFs differentiation and their
crosstalk with cancer cells becomes a crucial topic in cancer
research and could contribute to developing new therapeutic
strategies destroying the protumorigenic activity of CAFs
from cancer network [7, 8].
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Therefore, in this review article, we summarized the role
of metabolic reprogramming in CAFs differentiation and
pointed out CAFs metabolic reprogramming mechanisms
and cancer crosstalk.
Moreover, we discussed the significance of CAFs repro-
gramming mechanisms in cancer therapeutic responses and
focused on the potential therapeutic strategies targeting
molecules involved in CAFs reprogramming.
2. CAFs and Tumour
Microenvironment Hallmarks
Fibroblasts represent a heterogeneous population of mes-
enchymal cells characterized by an exceptional phenotypic
plasticity and capability to secrete large amounts of sol-
uble factors, ECM components, and extracellular vesicles
[11]. Under physiological conditions, fibroblasts regulate the
turnover of ECM, control tissue homeostasis, and participate
in wound healing and senescence [7]. On the other hand, in
solid tumours, normal fibroblasts (NFs) differentiate to CAFs
that coevolve with the disorder and alter the biochemical
and physical structure of the tumour microenvironment,
modifying the behaviour of the surrounding stromal and
cancer cells [11, 12]. Therefore, CAFs are the most prominent
noncancer cell type within the reactive stroma of many
solid tumours [13] and are often described as cells in a
constitutively activated state, sharing similarities with acti-
vated fibroblasts, named myofibroblasts, also found during
inflammation and wound healing [14]. It is noteworthy that
also in fibrotic diseases fibroblasts display a constitutively
activated myofibroblast-like phenotype [15].
Anyway, CAFs can derive from the activation of resident
fibroblasts or other precursor cells represented by bone
marrow derived mesenchymal stem cells, epithelial cells,
carcinoma cells, endothelial cells, pericytes, smooth muscle
cells, adipocytes, fibrocytes, stellate cells in pancreas and
liver, myoepithelial cells in breast, and pericryptal myofi-
broblasts of the gastrointestinal tract [11]. CAFs show high
expression of alpha-smooth muscle actin (𝛼-SMA), one of
the most significant markers of fibroblasts activation and
CAFs differentiation [11]. Furthermore, it is known that 𝛼-
SMA expression is induced by overexpression of hypoxia-
associated microRNA- (miR-) 210, which converts healthy
fibroblasts into CAFs-like cells [16].
However, 𝛼-SMA is not the only molecular marker
useful to identify CAFs. In fact, fibroblast activation pro-
tein (FAP), fibroblast-specific protein 1 (FSP1), osteonectin,
desmin, platelet-derived growth factor receptors (PDGFR)
𝛼 or 𝛽, neuron-glial antigen-2 (NG2), periostin (POSTN),
podoplanin (PDPN), tenascin-C (TNC), CD90/THY1, or
discoidin domain-containing receptor 2 (DDR2) and the
mesenchymal cell marker vimentin can be also considered
CAF markers [11, 17, 18].
Furthermore, it is noteworthy that circulating breast
CAFs in the peripheral blood of patients with metastatic
breast cancer were characterized as FAP+/𝛼-SMA+/Cyto-
keratin−/CD45− [17].
In breast and pancreatic carcinoma, CAFs can represent
up to 80% of the tumour mass, as a result of a widespread
desmoplasia that generates mechanical forces activating
fibroblasts [7]. Hence, desmoplasia and a lot of signalling
pathways in tumours can induce differentiation of CAFs,
which in turn promote tumour progression and metastasis
through the secretion of growth factors and chemokines [7].
In addition, desmoplasia and proliferating tumour cells gen-
erate high consumption of oxygen and the growing tumour
mass leads to progression of a hypoxic and acidic environ-
ment, towards which cancer cells must exhibit rapidly an
adaptive response.The adaptation to hypoxia and hyponutri-
ent conditions is sustained by the so-called “metabolic repro-
gramming”, i.e., a process in which changes of bioenergetics
and biosynthesis occur both in cancer cells and CAFs [3, 7].
In this way, the remodelling of cancer metabolism ensures
sufficient building blocks for biosynthesis and facilitates
cancer cells to survive a harsh hypoxic and nutrient-deprived
microenvironment by promoting tumour vascularization and
bypassing cancer immunity [19].
Hence, in tumour microenvironment, CAFs seem to be
enslaved by cancer cells to support their massive and uncon-
trolled proliferation and nutrients demand: in fact, CAFs
directly fuel tumour cells by producing and exporting high
energy metabolites, especially lactate, pyruvate, and ketone
bodies, which are used by adjacent cancer cells [20]. More-
over, metabolic reprogramming is not utilized for biosynthe-
sis in CAFs, whose proliferation rate is unexpectedly slower
than that of NFs but is needed for cancer cells to generate
energy, necessary to support cell division and to evade the
checkpoints that would normally block cell proliferation
under stressful condition [21].
3. Metabolic Signalling Pathways Associated
with CAFs Differentiation
It is known that, in the absence of an abnormally activated
tumour microenvironment, both genetic and epigenetic
mutations in cancer cells are not sufficient to sustain cancer
progression [8]. In fact, a necessary step for cancer initia-
tion and progression is represented by CAFs differentiation,
which can either occur at the early phase of cancer [9] or
surprisingly precede the genetic alterations of epithelial cells,
triggering the malignant transformation of adjacent cells
[22]. The constitutive activation of tumour stroma leading to
CAFs differentiation is associated with signalling pathways,
modulated mainly by tumour cells, with autocrine loops [14,
23, 24] and with CAFs metabolic reprogramming found in
many types of solid cancers, including breast, lung, prostate
and gastric cancer, head and neck squamous cell carcinoma
(HNSCC), and lymphomas [25, 26]. In particular, CAFs dif-
ferentiation can be induced by tumour cell-derived trans-
forming growth factor 𝛽 (TGF-𝛽), epidermal growth fac-
tor (EGF), PDGF𝛼, PDGF𝛽, basic fibroblast growth factor
(bFGF, also known as FGF2), interleukin 6 (IL-6), and
interleukin 1𝛽 (IL-1𝛽) [11, 18].
Moreover, it is known reactive oxygen species (ROS) to
regulate the metabolic reprogramming of both cancer cells
and CAFs, supporting the adaptation to oxidative stress that
triggers CAFs differentiation, tumorigenesis, and chemore-
sistance [4]. In the tumour microenvironment, cancer cells
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produce high levels of ROS deriving from mitochondrial
dysfunction, upregulation of NADPH oxidase 1 (NOX-1) and
NADPH oxidase 4 (NOX-4), and alterations of antioxidant
enzymes [7]. In particular, the mitochondrial dysfunction
is associated with a switch to aerobic glycolysis, known as
“Warburg effect”, whcih is an early step of carcinogenesis, and
can occur before the appearance of an important driver of the
metabolic switch in tumour cells: the hypoxia [4, 7]. However,
in cancer cells both “Warburg effect” and mitochondrial
malfunctioning trigger an increase of lactate and ROS levels
and a decrease of antioxidant molecules [7]. Therefore,
ROS can initiate a cascade of intra- and intercellular events
associated with metabolic switch in cancer [20] and CAFs





produced by cancer cells induces in CAFs an oxidative stress,
associated with the reduction of mitochondrial function and
the increase of both glucose uptake and ROS levels, leading to
CAFs differentiation [7]. Therefore, ROS generate a reactive
microenvironment, where the energy needed for cancer
cells proliferation is sustained by CAFs, whose activated
phenotype is constantly maintained [7].
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production by CAFs is due to an impaired TGF-
𝛽 signalling leading to the suppression of the antioxidant
enzyme glutathione peroxidase 1 (GPx1) [27].
TGF-𝛽 is a proteinwith a key role in CAFs differentiation,
enabling the increase of fibroblasts ROS that modulate 𝛼-
SMA expression [7]. In particular, it is known that TGF-𝛽
takes part in CAFs differentiation and metabolic regulation
[28]. Indeed, TGF-𝛽 induces differentiation of prostate CAFs
by triggering NOX-4 upregulation and ROS production [29].
Moreover, TGF-𝛽 triggers in fibroblasts increased oxidative
stress, autophagy/mitophagy, aerobic glycolysis, and down-
regulation of caveolin-1 (Cav-1): these alterations can extend
to surrounding fibroblasts and support cancer cell growth
[30]. Additionally, TGF-𝛽 signalling pathway is also linked
to the expression levels of some metabolic enzymes, such
as isocitrate dehydrogenase 1 (IDH1). In particular, Jun
Mi’s group showed a novel regulation network between cell
signalling pathway and cellular metabolism. TGF-𝛽 recep-
tor (TGFBR)-IDH1-Cav-1 axis triggers TGF-𝛽 signalling
in fibroblasts [28]. In turn, TGF-𝛽 signalling induces the
downregulation of IDH1 expression and this downregula-
tion enhances TGF-𝛽-activated canonical Smad signalling.
Despite IDH1 is an enzyme involved in the conversion of
isocitrate to 𝛼-ketoglutarate (𝛼-KG) in a NADP+-dependent
manner, its depletion increases cellular 𝛼-KG levels that sup-
press Cav-1 expression. The Cav-1 downregulation inhibits
TGFBR protein degradation and induces TGF-𝛽 signalling,
supporting and increasing the effect of this autocrine loop.
Furthermore, in murine xenograft tumour model, the protu-
morigenic effect of IDH1-knockdown fibroblasts is similar to
CAFs one [28].
High levels of ROS, produced by cancer cells, induce
oxidative stress in CAFs and lead to the production of
autophagosomes that fuse with lysosomes, with a consequent
mitochondria disruption andCav-1 degradation [20, 31]. Loss
of Cav-1, a marker of autophagy, glycolysis, and oxidative
stress [31], is also sufficient to induce a constitutive activated
phenotype in CAFs [32]. Ablation or mutation of Cav-1 is
one of the features of fibroblasts in tumour tissues [33].
The downregulation of Cav-1 in CAFs results in higher
ROS levels in cancer cells, which induce oxidative stress in
CAFs in a positive feedback loop [20]. Furthermore, Cav-
1 downregulation triggers a fibroblast shift toward catabolic
metabolism and promotes the mitochondrial activity of
adjacent cancer cells [34]. CAFs and cancer cells adopt
these self-stimulating and cross-communicating pathways to
maintain their protumorigenic potential. Additionally, the
downregulation of Cav-1 in fibroblasts is associated with the
induction of TGF-𝛽 signalling [30].
The increase of ROS levels in tumour environment also
induces the proinflammatory transcriptional factor NF𝜅B
activity in fibroblasts, leading to a CAF-like phenotype [35].
In fact, NFkB target gene cyclooxygenase-2 (COX-2) is found
upregulated in several solid tumours and in CAFs [36, 37]. In
addition, NFkB feeds the oxidative stress in CAFs causing a
defect in ROS detoxification through Gpx inhibition [38].
Other factors involved in fibroblasts metabolic repro-
gramming linked to CAFs formation are represented by
desmoplasia and hypoxia. In particular, desmoplasia of
solid tumours generatesmechanical forces converting fibrob-
lasts and other precursor to myofibroblasts and origi-
nates a hypoxic and acidic microenvironment that impairs
chemotherapeutic treatment [39]. Furthermore, hypoxic
microenvironment of desmoplastic cancer tissues produces
and maintains an oxidative stress condition, because hypoxia
is linked to mitochondrial ROS production and glycolytic
pathway [23].
Recent work studied the role of G-protein estrogen
receptor (GPER) and hypoxia in CAFs differentiation [40].
GPER is a seven-transmembrane-associated estrogen recep-
tor belonging to G-protein coupled receptors family, often
upregulated in breast CAFs [41]. GPER modulates cell sig-
nalling pathways and promotes breast cancer proliferation,
chemoresistance, and metastasis [42]. Furthermore, in breast
CAFs GPER biological function is linked to stimulatory
effects of estrogen and to regulation of the crosstalk between
cancer cells and CAFs [41]. GPER expression in breast CAFs
is associated with hypoxia-induced CAFs activation and
breast cancer cell invasion [40]. In fact, GPER knockdown
abrogates hypoxia driven CAFs formation, inhibits breast
cancer cell invasion induced by CAFs conditioned medium,
and abolishes hypoxia-activated connective tissue growth
factor (CTGF), vascular endothelial growth factor (VEGF),
and IL-6 secretion in CAFs [40].
It is known that exosomes secreted by cancer cells
are linked to CAFs differentiation [43]. In particular, exo-
somes from prostate cancer cells contain high levels of IL-
6 that modulates, together with other signalling molecules,
microenvironment remodelling and CAFs transdifferentia-
tion [44]. Moreover, increased IL-6 expression has been also
detected in breast and ovarian CAFs [37]. Additionally, it
is noteworthy that IL-6 links CAFs inflammation to the
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enhancement of glycolysis: this process could be associated
with expression of the glycolytic enzymes hexokinase 2 (HK2)
and 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase-
3 (PFKFB3) induced by IL-6 [43, 45].
4. CAFs Metabolic Reprogramming and
Cancer Crosstalk
The most of cancer cells do not rely primarily on mitochon-
drial oxidative phosphorylation (OXPHOS) but can produce
energy, needed for cellular processes, via the conversion of
glucose into lactate, despite the presence of sufficient oxygen
[5, 46]. Cancer cells in the solid tumour core have to assemble
a compensatory environment around them, in which CAFs
become their metabolic slaves providing crucial metabolic
intermediates for adenosine triphosphate (ATP) synthesis
[32, 47]. Hence, CAFs undergo metabolic reprogramming
switching towards a more glycolytic phenotype, whereas
the cancer cells rely more on their mitochondrial routes
of energy production via OXPHOS. In fact, it has been
shown that MCF7 breast cancer cells generate 80% of their
ATP through mitochondrial respiration [48]. Additionally,
inhibiting glycolysis in neoplastic cells restoresmitochondrial
OXPHOS, demonstrating that oxidative metabolism remains
functional in most glycolytic cancer cells [4]. These findings
are the antithesis of the classical Warburg’s hypothesis which
assumes the tumour cells to be highly glycolytic in nature and
to have an impaired mitochondrial activity. Hence, this alter-
native idea of aerobic glycolysis in CAFs and not in cancer
cells, as previously thought, supporting the oxidative tumour
mass was termed as the “reverse Warburg hypothesis” [49–
51]. “The reverse Warburg effect” can be explained by a two-
compartment tumour metabolism model, in which anabolic
cancer cells and catabolic CAFs are metabolically coupled.
Briefly, catabolic CAFs, through aerobic glycolysis, generate
higher levels of energy-rich fuels, to feed mitochondrial
OXPHOS in the adjacent anabolic cancer cells [20].This two-
compartment model has been further amplified in a three-
compartment tumour metabolism model, in which catabolic
stromal and catabolic cancer cells are metabolically coupled
to anabolic cancer cells, via catabolite transporters (MCTs)
(Figure 1). This metabolite compartment asymmetry further
shows the complexity of tumour ecosystem, demonstrating
that cells with different metabolic phenotype coexist and act
together to sustain tumour growth and diffusion (Figure 1)
[31].
Glycolysis-related enzymes, such as HK2 and 6-
phosphofructokinase liver type (PFKL), are considerably
upregulated in CAFs, substantiating their glycolytic nature
[32, 43, 52]. In particular, HK2 is a pivotal glycolytic
enzyme that is overexpressed in tumours and contributes to
“Warburg effect” [53]. In a CAF model, HK2 protein levels
increase during CAFs differentiation induced by TGF-𝛽1.
Furthermore, HK2 upregulates p27 protein expression
through its downstream metabolite 𝛼-KG. In turn p27
inhibits cyclin-dependent kinase 2 (CDK2) and activates
the G1/S checkpoint. This regulatory mechanism connects
glycolysis to cell cycle control: in fact, HK2 enzyme regulates
both glycolysis and a cell cycle checkpoint [53].
The high rate of glycolysis is believed to be one of the
driving forces behind the supportive role of CAFs in tumour
growth. However, up to now, the molecular mechanisms res-
ponsible for this change achieved inCAFs are not fully under-
stood and defined. A large number of possible mechanisms
has been proposed and explored to explain the metabolic
reprogramming associatedwith the upregulation of glycolysis
in CAFs. CAFs are reprogrammed by contact with cancer
cells toward a glycolytic phenotype, increasing their glucose
upload and their delivery of lactate and pyruvate, the end
products of glycolysis [47, 54]. In particular, the entry of
glucose into the cells is allowed by enhanced expression of
GLUT-1. It is known that oncogene like cMyc enhances the
metabolic flux and glucose uptake by increasing the lactate
dehydrogenase-A (LDH-A) but also GLUT-1 expression [55].
Moreover, downregulation of miR-186 increases GLUT-1
protein level during CAFs formation. Therefore, miR-186
modulates glycolysis through GLUT-1 [56].
The extrusion of lactic acid, instead, is assured by mono-
carboxylate transporter-4 (MCT-4). Specifically, lactate is
always extruded by MCT-4 in association with the H+,
leading to the acidification of tumour microenvironment
[47]. Increased acidity causes activation of matrix metallo-
proteinase-9 (MMP-9) and enhances epithelial mesenchymal
transition (EMT) of neighboring cancer cells, positively
affecting tumour progression [57]. Hence, increased gly-
colysis, showed by excessive lactate production, leads to
upregulation of MCT-4 in CAFs such as observed in breast
and bladder CAFs [58].
On the other hand, monocarboxylate transporter 1
(MCT-1) is the transporter responsible for lactate influx
into cancer cells, as can be observed in the osteosarcoma
cells [59, 60]. Lactate is efficiently exploited by cancer cells
themselves both to obtain energy and biomolecules through
enhanced anabolism and to fuel OXPHOS. This evidence
further strengthens the concept of metabolic reprogramming
in tumour microenvironment.
As mentioned above, extracellular acidification is an
important feature for tumour progression and it has been
mainly correlated with metabolic reprogramming of tumour
cells toward Warburg metabolism [61]. Carbonic anhydrases
(CAs) are a family of zinc metalloenzymes that rapidly catal-
yse the hydration of carbon dioxide, producing bicarbonate
and protons. At least thirteen human active isoenzymes
belong to this family and, in particular, CA IX is a transmem-
brane enzyme endowed with an extracellular membrane-
bound catalytic domain that contributes to acidification
of the outer microenvironment. Within tumours CA IX
is mainly distributed in perinecrotic areas, likely due to
its acknowledged regulation by hypoxia through hypoxia-
inducible factor 1 𝛼 (HIF-1𝛼). Fiaschi et al. showed an
upregulation of CA IX in CAFs upon contact with prostate
carcinoma cells, concurring to extracellular acidification [61].
It is known that GPER estrogen receptor is able to mod-
ulate CAFs metabolic reprogramming. In particular, Yu et al.
demonstrated that GPER is transferred from the nucleus to
the cytoplasm of estrogen-stimulated breast CAFs only upon
a direct contact with breast tumour cells. The cytoplasmic
GPER, through the activation of GPER/cAMP/PKA/CREB
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Figure 1: Metabolic reprogramming of tumour microenvironment, a three-compartment model. Tumour growth and progression are
sustained by a metabolic interplay between catabolic tumour cells, normal fibroblasts, and catabolic activated CAFs that contribute to the
anabolic reprogramming of cancer cells. This crosstalk is mediated by ROS, soluble factors, energy-rich fuels, and catabolite transporters,
such as monocarboxylate transporter 1 (MCT-1), monocarboxylate transporter 4 (MCT-4), and glucose transporter protein (GLUT-1). In
particular, mitochondrial dysfunction in catabolic cancer cells is associated with glycolysis switch (“Warburg effect”).These catabolic tumour
cells show an increase of glucose uptake, upregulation of NOX-1 and NOX-4, and high level both of ROS and energy-rich fuels extrusion.
The differentiation of normal fibroblasts into activated CAFs is ROS modulated. ROS, produced by catabolic cancer cells, upregulate HIF-1𝛼
whose levels are also increased by the loss of caveolin-1 (Cav-1). These events are involved in CAFs glycolytic switch. Hence, CAFs show a
catabolic phenotype characterized by an inhibition of OXPHOS, a reduction of proliferation marker Ki-67, and release of energy-rich fuels.
These molecules, represented by lactate, pyruvate, ketone bodies, etc., feed cancer cells that acquire an anabolic phenotype, where the high
request of ATP is satisfied by an efficient mitochondrial OXPHOS.
signalling, induces the energy metabolism switch of CAFs
towards a “Warburg-like state”, supporting the critical role of
CAFs and tumour cells crosstalk in themetabolic reprogram-
ming and in breast cancer progression [25].
Another process associated with the metabolic remod-
elling in CAFs implicates tricarboxylic acid (TCA) cycle
downregulation. Zhang et al. identified Krebs cycle enzyme
isocitrate dehydrogenase 3𝛼 (IDH3𝛼) downregulation as
a critical marker for switching energy metabolism from
OXPHOS to glycolysis in TGF-𝛽1/PDGF-induced CAFs [52].
Moreover, miR-424 downregulates IDH3𝛼 whose overex-
pression prevents the differentiation of NFs to CAFs. In
primary fibroblasts, with IDH3𝛼 knockdown, glucose uptake
and lactate production are increased, whereas oxygen con-
sumption is decreased [52]. In contrast, IDH3𝛼 overexpres-
sion not only reduces the basal level of TGF-𝛽-stimulated
glucose uptake but also inhibits TGF-𝛽-induced lactate pro-
duction with increased basal oxygen consumption. Further-
more, downregulation of IDH3𝛼 decreases the effective level
of 𝛼-KG by reducing the ratio of 𝛼-KG to fumarate and
succinate, required for prolyl hydroxylase domain-containing
protein 2 (PHD2) activity. PHD2 is a HIF-1 downregulator
and its inhibition allows HIF-1𝛼 protein stabilization in the
cytosol [62, 63]. Under normoxic condition, HIF-1 is des-
tined for ubiquitination and degradation that instead is pre-
vented in oxygen deprived conditions leading to its accu-
mulation in the cytosol [64]. The stabilization of HIF-1𝛼
and its subsequent nuclear translocation is considered as
one of the pivotal events inside the hypoxic solid tumour
core. HIF-1𝛼 is associated with the upregulation of about 100
genes, several of which are directly related to the glycolytic
pathway [65]. Hence, the accumulation of HIF-1𝛼, in turn,
promotes glycolysis by increasing the uptake of glucose and
inhibiting OXPHOS by upregulating NADH dehydrogenase
ubiquinone 1 alpha subcomplex, 4-like 2, (NDUFA4L2)
a negative regulator of mitochondrial complex 1 [52]. In
addition, a previous study showed that HIF-1𝛼 upregulates
NDUFA4L2 expression during hypoxia in mouse embryonic
fibroblasts (MEFs) and tumour cells [66]. Taken together,
these data indicate that IDH3𝛼 downregulation upregulates
HIF-1𝛼 and NDUFA4L2, which in turn promotes glycolysis
and inhibits OXPHOS, respectively, providing an insight into
the initiation of “Warburg-like effect” in CAFs.
HIF-1 is not only activated upon low O
2
concentration
but also under normoxic conditions. HIF-1𝛼 stabilization is
brought about by a loss of Cav-1, leading to an induction of
oxidative stress in CAFs creating a pseudo-hypoxic state [67].
A proteomic analysis of Cav-1-deficient fibroblasts in human
breast cancer tissues revealed an increased transcription
level of glycolytic enzymes under normoxic conditions [32].
Subsequent study showed that loss of Cav-1 in mesenchymal
stromal cells leads to increased aerobic glycolysis via activa-
tion of HIF-1 andNFkB favouring tumour growth [67, 68]. In
support of this hypothesis, a study performed in a xenograft
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model evidenced that the HIF-1𝛼-dependent activation of
autophagy in stromal cells greatly enhances the tumorigenic-
ity of MDA-MB-231 breast cancer cells [34]. Moreover, HIF-
1𝛼 expression is shown to be directly associated with themain
exporter of lactate in CAFs, MCT-4 [31].
As shown by Balliet and colleagues, the downregulation
of mitochondrial transcription factor A (TFAM) in fibrob-
lasts is linked to Cav-1 dysregulation, with a consequent
induction of oxidative stress, mitochondrial dysfunction, and
aerobic glycolysis in the tumour microenvironment. TFAM





are sufficient to promote tumour growth [69]. Finally, the
Cav-1-knockout fibroblastsmetabolically cooperate with can-
cer cells by enhancing lactate production for mitochondrial
respiration in anabolic cancer cells [32] Taken as a whole,
the loss of stromal Cav-1 is very important in the metabolic
reprogramming of CAFs.
For the metabolic crosstalk between CAFs and cancer
cells, the HIF-1-driven transcriptional activity is important
and can also be mediated by activation of sirtuin1 (SIRT1)
signalling that ensures deacetylation of peroxisome prolif-
erator activated receptor gamma coactivator 1𝛼 (PGC1-𝛼)
or by mitochondrial deacetylase SIRT3 downregulation that
increases the level of inactive superoxide dismutase 2 (SOD2)
acetylated [47, 54]. These events lead to increased mito-
chondrial function associated with overproduction of ROS
and subsequent functional regulation of pyruvate kinase M2
(PKM2). The expression of PKM2 is also induced in Cav-1-
knockdown fibroblasts and is a sufficient condition to trigger
aerobic glycolysis [34]. In cancer cells after contact with their
stromal CAFs, PKM2 acts by regulating OXPHOS addic-
tion, instead of the classical Warburg glycolytic metabolism.
Indeed, upon CAFs contact PKM2 becomes oxidized by ROS
delivered by hyperactive mitochondria, as well as tyrosine
phosphorylated by activated Src kinase. PKM2 migrates into
the nucleus and recruits both HIF-1 and associate embryo-
chondrocyte expressed gene-1 (DEC1), thereby repressing
expression of miR-205, driving a pleiotropic transcrip-
tional response leading to metabolic reprogramming toward
OXPHOS and enhancing survival and EMT [47].
In addition to lactate, previous studies have shown that
CAFs also increase the production of other nutrients like
glutamine and ketone bodies, which emerge as possible fuel
sources for anabolic metabolism or OXPHOS, utilized by
tumour cells in support of their growth [31, 70].
A vast array of studies indicates that tumour cells induce a
metabolic overdrive in CAFs, also almost to the point of self-
destruction of cell’s own organelles and protein molecules,
inducing autophagy and mitophagy [9, 71]. These are pro-
cesses by which CAFs recycle the important biomolecules
and metabolic precursors to generate lactate and pyruvate
via aerobic glycolysis. These two metabolites are continually
channelled towards the nearby tumour cells, which utilize
them to manufacture additional ATPmolecules via oxidative
mitochondrial metabolic pathways [43, 72].
Previous studies have demonstrated that loss of Cav-1
in stromal cells enhances the transcription of TGF-𝛽 target
genes, such as CTGF. It is known that CTGF overexpression
in fibroblasts induces an autophagy/mitophagy program,
only downstream from a loss of stromal Cav-1 [34]. CAFs
adopt this self-destructive mechanism to create a nutrient-
rich microenvironment by release of lactate, ketone bodies,
and glutamine, metabolically supporting cancer growth [73].
Furthermore, Santi et al. showed that CAFs, using
microvesicles (MVs) as cargo, are also able to transfer a large
amount of proteins and lipids to neighboring cancer cells,
thereby contributing to sustain the high proliferation rate
of tumour cells [74]. Since several transferred proteins are
metabolic enzymes,MVs have an important role inmetabolic
reprogramming of cancer cells due to CAFs contact.
Additionally, also CAF-derived exosomes are able to
induce a metabolic reprogramming in cancer cells after their
uptake [75]. Zhao et al. demonstrated that CAF-derived
exosomes contain intact metabolites, like amino acids, lipids,
and TCA-cycle intermediates that are vehiculated in cancer
cells to support their growth [76].
To sum up, regarding the exploration and the function of
the mechanisms underlying this metabolic reprogramming,
it appears that the metabolic behaviour sustains growth of
cancer cells at the clear expenses of the stromal counterpart
with a proliferation rate of CAFs lower than NFs.
Furthermore, the aerobic glycolysis and concomitant
increase in glucose uptakemake the positron emission tomo-
graphy (PET) an imaging technology, which uses glucose
analog tracer for tumour diagnosis, able to detect glucose
consumption in stroma rather than strictly in cancer cells [4].
In fact, it is noteworthy that in the tumour mass CAFs have
the largest increases in glucose uptake.Martinez-Outschoorn
et al. suggested that the PET scanning with 2-[18F]-2-deoxy-
D-glucose (18F-FDG), currently used tomeasure the extent of
fibrosis in a number of human diseases, such as pulmonary
fibrosis, postsurgical scars, and arthritis, may specifically
detect the tumour stroma in cancer patients, by visualizing
the glucose uptake and thereby the “Warburg effect” in CAFs,
rather than in cancer cells [77].
5. Therapeutic Responses to
CAFs Metabolic Reprogramming
The metabolic symbiosis between cancer cells and stromal
cells is increasingly recognized as the main driver of tumour
progression, metastasis, and therapeutic failures.
The mutagenic and oxidative stress, propagated from
cancer cells to CAFs, and vice versa, generates a very
unstable and lethal microenvironment, in which cancer cells
exploit metabolically CAFs to support their own survival
and growth. In fact, during metabolic symbiosis, CAFs
help cancer cells to overcome cellular and pharmacological
stress reducing apoptosis [78] and increasing mitochondrial
activity in cancer cells [51]. Indeed, cancer cells that acquire
drug resistance are characterized by increased mitochondrial
mass, OXPHOS activity, and antioxidant capacity. Initially,
anticancer drugs reduce the tumour mass, by damaging or
killing the major population of cancer cells. Unfortunately,
this initial cancer regression often precedes the appearance
of new and more vigorous tumours due to the surviving
residual cancer cells that resist the pharmacological stress
via mitochondrial adaptation [79]. Martinez-Outschoorn et
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al. demonstrated that two potent mitochondrial “poisons”,
namely, metformin and arsenic trioxide (ATO), are able to
resensitize breast cancer cells, whose tamoxifen resistance has
been induced by CAFs [78]. Moreover, metformin, usually
used in the treatment of diabetes, is currently undergoing
phase 2/3 clinical trials as adjuvant therapy in several cancer
types, for its capacity to restore Cav-1 expression in CAFs
[80]. In fact, metformin, through AMP activated protein
kinase (AMPK) induction, inhibits autophagy, which is the
process involved in Cav-1 degradation. In addition, met-
formin is currently utilized in phase 1 study in combination
with a specific inhibitor of autophagy, called temsirolimus, to
treat patients with aggressive B-cell lymphoma [81].
Furthermore, in the last few years, chloroquine under-
went a clinical trial known as Preventing Invasive Breast
Neoplasia with chloroquine (PINC) because of its ability to
rescue the expression of Cav-1 in CAFs via the inhibition of
autophagy [82].
However, metabolic symbiosis between CAFs and cancer
cells can represent an adaptive response to cancer therapy,
which results in drug resistance. In mouse models of breast
tumour, cancer cells overcome nintedanib treatment shifting
towards a hyperglycolytic metabolism and inducing the over-
expression of MCT-4 [83], a well-known marker of oxidative
stress inCAFs [58].The genetic ablation ofMCT-4 expression
is sufficient to overcome therapy resistance and enhance the
antitumour effect of nintedanib [83]. Therefore, MCTs offer
a great potential for developing new anticancer therapies:
in support of this notion, several studies have demonstrated
that the genetic disruption of MCT-1 or MCT-4 blocks breast
tumour growth [84] and sensitizes cancer cells to treatment
with phenformin, an inhibitor of mitochondrial complex 1
[85].
Moreover, growing evidence suggests that the cyto-
plasmic stromal GPER, involved in the aerobic glycolysis
switch in CAFs, as already described in this review, is also
implicated in the development of multiple drug resistance
to classical clinical drugs, such as tamoxifen, herceptin,
and epirubicin [25]. In fact, drug-resistant tumours show
high levels of the cytoplasmic stromal GPER and extremely
increased aerobic glycolysis. This is confirmed by 18F-FDG
PET/CT analysis showing an important association between
the GPER/cAMP/PKA/CREB pathway of stromal fibroblasts
and 18F-FDG uptake in primary or drug-resistant tumours
[25]. Hence, the cytoplasmic GPER in CAFs may represent
another promising target for cancer therapy to rescue the
drug sensitivity in patients with breast cancer [25].
Furthermore, the increasing knowledge about the capac-
ity of ROS production and oxidative stress to induce in CAFs
an inflammatory phenotype and tumour stroma metabolic
coupling [86] supports the idea that treatment with antiox-
idants and/or anti-inflammatories may allow the metabolic
separation of cancer cells from CAFs, leading to cancer
cells death and consequently tumour regression. Martinez-
Outschoorn and colleagues demonstrated that treatment
with antioxidants, such as N-acetyl-cysteine (NAC), met-
formin, and quercetin or nitric oxide (NO) inhibitors, like L-
NAME, is useful to reverse CAFs phenotypes, rescuing Cav-
1 expression in fibroblasts [87]. The antineoplastic activity of
metformin is also associatedwith its ability to reduce endoge-
nous ROS production, oxidative stress, and related DNA
damage and mutations [88]. In addition, the antioxidants
NAC, quercetin, metformin, and chloroquine dramatically
reduce MCT-4 expression in CAFs [89, 90]. In fact, Monti et
al. demonstrated in a clinical trial that NAC, reducingMCT-4
expression in the tumour stroma of cancer patients, decreases
carcinoma cell proliferation rates in women with stages 0 and
I breast cancer. This pilot clinical trial showed NAC effec-
tiveness and safety in breast cancer treatment [91]. Moreover,
NAC in combination with topotecan underwent a phase 2
clinical trial in ovarian cancer patients, based on their role in
the regulation of Cav-1, MCT-4, and HIF-1𝛼 expression [20].
Accumulating evidence suggests that nonsteroidal anti-
inflammatory drugs (NSAIDs), such as aspirin, celecoxib,
and diclofenac, are associated with a decreased risk of
colorectal, lung carcinomas, and other tumours [92–94]. In
particular, the anticancer effect of aspirin may be explained
by its ability to affect the metabolism in cancer. In fact,
aspirin both triggers the suppression of de novo lipogenesis in
prostate and lung cancers [95] and induces posttranslational
modifications of enzymes of the glycolytic pathway and
mitochondrial proteins, leading to a change in their function
[96].
LDH-A, an enzyme involved in the conversion of pyru-
vate to lactate, is highly expressed in Cav-1 (−/−) null stromal
cells [97]. For this reason, a selective suppressor of LDH-
A, named FX11, able to reduce the progression of human
lymphoma and pancreatic cancer xenografts [98] was studied
by National Cancer Institute’s Experimental Therapeutics
Program (NExT) [99].
As described in this review, low pH in tumours is the
consequence of high metabolic activities and an impor-
tant driver of tumour progression and aggressiveness. For
this reason, many drugs targeting proton transporters have
been suggested as anticancer drugs. In particular, a CA IX
inhibitor, indisulam, underwent a phase 2 clinical trial for
the treatment of melanoma, lung, pancreatic, and metastatic
breast cancers, although no significant efficacy was observed
in a phase 2 clinical trial on non-small cell lung cancer [100].
In an orthotopic mouse model for ovarian carcinoma,
the simultaneous depletion of glutamine synthetase (GS),
upregulated in CAFs duringmetabolic coupling, and glutam-
inase (GLS), expressed in cancer cells, results in a greater
reduction of tumour growth and metastasis with respect
to monotherapy. The concomitant use of GS and GLS
inhibitors may represent a novel and lethal approach to target
tumours and disrupt themetabolic crosstalk between stromal
and cancer cells [101]. Hence, the inhibition of enzymes
associated with energy-rich fuels overproduction in CAFs
can be considered as new promising therapeutic targets in
cancer patients treatment [97]. Indeed, the reduction of the
bioenergetic support of CAFs in the tumourmassmay induce
starvation and/or death of cancer cells, leading to cancer
regression [86].
HK2 is considered an important anticancer drug target.
In fact, HK2 inhibits mitochondrial apoptosis by direct inser-
tion in the mitochondrial outer membrane and induces drug
resistance. Due to its contribution in regulating apoptosis and
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Table 1: List of several compounds targeting CAFs metabolism.
Compound Mechanism of action Pathway target Refs




[80, 87, 89, 90]
Quercetin ↑ Cav-1; ↓MCT-4 Oxidative stressLactate transporter [87, 89]
Chloroquine ↑ Cav-1; ↓MCT-4 AutophagyLactate transporter [82, 89]
NAC ↑ Cav-1; ↓MCT-4 Oxidative stressLactate transporter [20, 89–91]
L-NAME ↑ Cav-1 Oxidative stressMitochondrial activity [87]
FX11 ↓ LDH-A Lactate production [98, 99]
Indisulam ↓ CA IX Microenvironment acidification [100]
3-BP ↓HK-2 Glycolysis [102]
T-Lipo-3-BP ↓HK-2 Glycolysis [103]
cellular bioenergetics, HK2 inhibitors have been developed
[75]. In particular, as discussed by Gatenby and Gillies the
HK2 inhibitor 3-bromopyruvate (3-BP) is able to reduce
ATP reserves and thereby reverse chemoresistance [102].
Moreover, in order to reduce the adverse effects of 3-BP, due
to its nonspecific delivery and distribution to healthy organs,
3-BP was encapsulated into a liposomal nanocarrier (T-Lipo-
3-BP) and specifically delivered to the tumour mass after
systemic administration in a mouse tumour model. Zhang et
al. demonstrated that T-Lipo-3-BP nanoparticles represent a
safe and efficient controlled release system: this novel thera-
peutic approach abolishes the severe side effects, such as the
hepatotoxicity of 3-BP, and suppresses tumour growth [103].
Unfortunately, one of the most side effects of cancer
chemotherapy is represented by the growth of a second
primary tumour that does not derive frommetastatic growth
[104]. This process could be associated with activation
of stromal fibroblasts induced by chemotherapy drugs. In
particular, recent in vitro study showed that treatment of
stromal fibroblasts with commonly used anticancer drugs
induces CAFs differentiation [104]. Furthermore, upon treat-
ment, stromal fibroblasts trigger stemness, antioxidant, and
immune response in breast cancer cells. Hence, new and
specific antistromal therapies must be necessarily added to
the traditional antitumour drugs to intensify the fight against
cancer (Table 1).
6. Conclusions
Tumour initiation and progression need metabolic repro-
gramming of tumour microenvironment. Additionally, solid
tumours can be considered as metabolically heterogeneous
diseaseswhere several cell types and energetic pathways coex-
ist and collaborate to assure the growth and progression of
pathology. In this biological scenario, CAFs could represent
the main cell type regulating the homeostasis and crosstalk
within cancer tissues. This hypothesis is supported by the
heterogeneity of fibroblasts cell population associated with
functional diversity and by capability of activated fibroblasts
of modulating inflammation process [105–107] that is one of
the main leading causes of cancer progression [108].
The importance of CAFs in tumour pathogenesis is
further strengthened by their involvement in cancer initia-
tion, metastasis, angiogenesis, lymphangiogenesis, metabolic
reprogramming, and therapy resistance [9].
Moreover, the presence of breast CAFs detected in the
peripheral blood of patients withmetastatic breast cancer [10]
confirms the dramatic adaptability of this cell type.
Therefore, fromour point of view, themetabolic slavery of
CAFs within tumour microenvironment represents a central
topic of the oncological research. In particular, the devel-
opment of strategies committed to inactivate CAFs myofi-
broblastic phenotype [109] and to disconnect the metabolic
crosstalk between CAFs and cancer cells could contribute to
eliminate protumorigenic activity of CAFs in cancer network.
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